PL3538528T3 - Amidy pirolu jako inhibitory integryny alfa v - Google Patents

Amidy pirolu jako inhibitory integryny alfa v

Info

Publication number
PL3538528T3
PL3538528T3 PL17801236T PL17801236T PL3538528T3 PL 3538528 T3 PL3538528 T3 PL 3538528T3 PL 17801236 T PL17801236 T PL 17801236T PL 17801236 T PL17801236 T PL 17801236T PL 3538528 T3 PL3538528 T3 PL 3538528T3
Authority
PL
Poland
Prior art keywords
alpha
integrin inhibitors
pyrrole amides
pyrrole
amides
Prior art date
Application number
PL17801236T
Other languages
English (en)
Inventor
Guohua Zhao
James Mignone
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3538528T3 publication Critical patent/PL3538528T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
PL17801236T 2016-11-08 2017-11-07 Amidy pirolu jako inhibitory integryny alfa v PL3538528T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418833P 2016-11-08 2016-11-08
PCT/US2017/060392 WO2018089360A1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors
EP17801236.5A EP3538528B1 (en) 2016-11-08 2017-11-07 Pyrrole amides as alpha v integrin inhibitors

Publications (1)

Publication Number Publication Date
PL3538528T3 true PL3538528T3 (pl) 2021-05-31

Family

ID=60409438

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17801236T PL3538528T3 (pl) 2016-11-08 2017-11-07 Amidy pirolu jako inhibitory integryny alfa v

Country Status (23)

Country Link
US (1) US10717736B2 (pl)
EP (1) EP3538528B1 (pl)
JP (1) JP7220653B2 (pl)
KR (1) KR102515507B1 (pl)
CN (1) CN110139864B (pl)
AU (1) AU2017359030A1 (pl)
BR (1) BR112019009293A2 (pl)
CA (1) CA3042693A1 (pl)
CY (1) CY1123893T1 (pl)
DK (1) DK3538528T3 (pl)
EA (1) EA201991124A1 (pl)
ES (1) ES2852351T3 (pl)
HR (1) HRP20210228T1 (pl)
HU (1) HUE053620T2 (pl)
IL (1) IL266469A (pl)
LT (1) LT3538528T (pl)
MX (1) MX377293B (pl)
PL (1) PL3538528T3 (pl)
PT (1) PT3538528T (pl)
RS (1) RS61453B1 (pl)
SI (1) SI3538528T1 (pl)
SM (1) SMT202100089T1 (pl)
WO (1) WO2018089360A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509590A4 (en) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
CA3042710A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
BR112019012515A2 (pt) 2016-12-29 2019-11-19 Saint Louis University antagonistas de integrina
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
IL297530B2 (en) 2017-02-28 2025-04-01 Morphic Therapeutic Inc (Alpha–V)(beta–6) integrin inhibitors
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6
EP3843727A4 (en) * 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
AU2019373244B2 (en) 2018-10-30 2022-05-26 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
KR20230169979A (ko) * 2021-03-10 2023-12-18 다이스 몰레큘스 에스브이, 인크. 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
CA2309204A1 (en) * 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists
JP2002508323A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
AR015759A1 (es) * 1998-04-10 2001-05-16 Searle & Co Compuesto derivado heterociclicos de glicil d-alanina, composicion farmaceutica que lo contiene y metodo para tratar afecciones
EP1105389A4 (en) 1998-08-13 2001-10-17 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
AUPP646598A0 (en) 1998-10-12 1998-11-05 Fujisawa Pharmaceutical Co., Ltd. New processes for producing alpha-alanine derivative
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
CN1414966A (zh) * 1999-11-08 2003-04-30 麦克公司 用于制备咪唑烷酮αu蛋白拮抗剂的方法和中间体
GB0001447D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6855722B2 (en) 2001-01-29 2005-02-15 Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
DE60335118D1 (de) * 2002-08-16 2011-01-05 Janssen Pharmaceutica Nv Piperidinylverbindungen, die selektiv an integrine binden
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
ES2308227T3 (es) * 2003-10-01 2008-12-01 Merck Patent Gmbh Antagonistas de integrina alfavbeta3 y alfavbeta6 como agentes antifibroticos.
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
WO2011090929A1 (en) * 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
EP2953948B1 (en) * 2013-02-07 2017-09-27 Scifluor Life Sciences, Inc Fluorinated integrin antagonists
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2016219906B2 (en) 2015-02-19 2020-10-01 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use

Also Published As

Publication number Publication date
CN110139864B (zh) 2022-08-23
KR102515507B1 (ko) 2023-03-28
EP3538528A1 (en) 2019-09-18
EA201991124A1 (ru) 2019-10-31
CY1123893T1 (el) 2022-05-27
EP3538528B1 (en) 2020-12-23
HUE053620T2 (hu) 2021-07-28
AU2017359030A1 (en) 2019-06-20
ES2852351T3 (es) 2021-09-13
DK3538528T3 (da) 2021-02-15
IL266469A (en) 2019-07-31
MX377293B (es) 2025-03-07
MX2019005233A (es) 2019-08-12
KR20190076031A (ko) 2019-07-01
SI3538528T1 (sl) 2021-03-31
JP7220653B2 (ja) 2023-02-10
US10717736B2 (en) 2020-07-21
SMT202100089T1 (it) 2021-03-15
RS61453B1 (sr) 2021-03-31
WO2018089360A1 (en) 2018-05-17
CA3042693A1 (en) 2018-05-17
US20190256512A1 (en) 2019-08-22
CN110139864A (zh) 2019-08-16
HRP20210228T1 (hr) 2021-03-19
LT3538528T (lt) 2021-03-10
BR112019009293A2 (pt) 2019-07-30
PT3538528T (pt) 2021-02-16
JP2020500182A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
IL266469A (en) Pyrrol-amides as alpha-v-integrin inhibitors
ZA201905811B (en) Novel inhibitors
IL266470A (en) Monocyclic and spirocyclic compounds containing cyclobutane and aztidine as alpha-v-integrin inhibitors
IL255246A0 (en) Heterocyclic amides as kinase inhibitors
IL258180B (en) Heterocyclic compounds and their uses
IL272649B (en) AHR inhibitors and their uses
IL266465A (en) Azole amides and amines as alpha five integrin inhibitors
GB201605126D0 (en) Inhibitors and their uses
GB201708652D0 (en) Novel compounds and uses
IL246987A0 (en) Heteroaryl amides, preparations containing it and their uses
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
ZA201907136B (en) Ip6k inhibitors
IL274425A (en) Pyrrolopyrazine derivatives as alpha five integrin inhibitors
IL275375A (en) Pyrrolidine amides II are converted
IL275374A (en) Pyrrolidine amides I are converted
IL254916B (en) Inhibitors and their uses
IL262400A (en) Erbb inhibitors and uses thereof
GB201612860D0 (en) Inhibitors
IL251077B (en) Integrin inhibitors and their use
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
PL3209743T3 (pl) Zastosowanie foliowych materiałów licowych do polimerowego opakowania
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL251078A0 (en) Integrin inhibitors and their use
PL3268356T3 (pl) Związki heterocykliczne i sposoby ich stosowania
IL261644A (en) Oxalyl derivatives and their use as cyclophilin inhibitors